Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2015) Nationale VersorgungsLeitlinie (NVL) Prävention und Therapie von Netzhautkomplikationen bei Diabetes. (2. Auflage). http://www.leitlinien.de/nvl/diabetes/netzhautkomplikationen. Zugegriffen: 17. Dez. 2019
2. Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, Bressler NM, Elman MJ, Ferris FL, Gardner TW, Jampol LM, Martic DF, Melia M, Stockdale CR, Beck RW (2018) Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA Ophthalmol 136:1138–1148. https://doi.org/10.1001/jamaophthalmol.2018.3255
3. Lang GE, Stahl A, Voegeler J, Quiering C, Lorenz K, Spital G, Liakopoulos S (2019) Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy—the PRIDE study. Acta Ophthalmol. https://doi.org/10.1111/aos.14312
4. Sivaprasad S, Prevost AT, Bainbridge J, Edwards RT, Hopkins D, Kelly J, Luthert P, Murphy C, Ramu J, Sarafraz-Shekary N, Vasconcelos J, White-Alao B, Hykin P (2015) Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial. BMJ Open 5(9):e8405. https://doi.org/10.1136/bmjopen-2015-008405
5. Gupta MP, Kiss S, Chan RVP (2018) Reversal of retinal vascular leakage and arrest of progressive retinal Nonperfusion with monthly anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy. Retina 38(9):e74–e75. https://doi.org/10.1097/IAE.0000000000002261
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献